CA2768598A1 - Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes - Google Patents

Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes Download PDF

Info

Publication number
CA2768598A1
CA2768598A1 CA2768598A CA2768598A CA2768598A1 CA 2768598 A1 CA2768598 A1 CA 2768598A1 CA 2768598 A CA2768598 A CA 2768598A CA 2768598 A CA2768598 A CA 2768598A CA 2768598 A1 CA2768598 A1 CA 2768598A1
Authority
CA
Canada
Prior art keywords
seq
module
conjugate
covalently linked
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2768598A
Other languages
English (en)
French (fr)
Inventor
Christophe J. Echeverri
Birte Soennichsen
Reinhard Waehler
Mike Werner Helms
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cenix BioScience GmbH
Original Assignee
Cenix BioScience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenix BioScience GmbH filed Critical Cenix BioScience GmbH
Publication of CA2768598A1 publication Critical patent/CA2768598A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2768598A 2009-07-22 2010-07-22 Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes Abandoned CA2768598A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22766909P 2009-07-22 2009-07-22
US61/227669 2009-07-22
PCT/EP2010/004512 WO2011009624A1 (en) 2009-07-22 2010-07-22 Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes

Publications (1)

Publication Number Publication Date
CA2768598A1 true CA2768598A1 (en) 2011-01-27

Family

ID=42731966

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2768598A Abandoned CA2768598A1 (en) 2009-07-22 2010-07-22 Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes

Country Status (5)

Country Link
US (1) US20120258104A1 (cg-RX-API-DMAC7.html)
EP (1) EP2456470A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012533587A (cg-RX-API-DMAC7.html)
CA (1) CA2768598A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011009624A1 (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX354016B (es) 2010-09-15 2018-02-07 J Mrsny Randall Sistemas y metodos de suministro de agentes bioactivos mediante el uso de secuencias transportadoras derivadas de toxinas.
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
SI2646470T1 (sl) 2010-11-30 2017-05-31 F. Hoffmann-La Roche Ag Protitelesa proti receptorjem antitransferina in njihova uporaba za prenos terapevtskega enoverižnega variabilnega fragmenta (scfv) prek krvno-možganske pregrade
US20140065172A1 (en) * 2011-01-26 2014-03-06 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
WO2012113413A1 (en) * 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
US9045750B2 (en) * 2011-03-18 2015-06-02 Yuelong Ma Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3
US9580708B2 (en) * 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
CN104039961A (zh) * 2012-01-07 2014-09-10 株式会社博纳克 具有氨基酸骨架的单链核酸分子
WO2013127829A1 (en) * 2012-02-27 2013-09-06 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
EP2850185A4 (en) 2012-05-16 2015-12-30 Rana Therapeutics Inc COMPOSITIONS AND METHOD FOR MODULATING UTRN GENE EXPRESSION
KR20150030205A (ko) 2012-05-16 2015-03-19 라나 테라퓨틱스, 인크. Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
CA2873779A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating mecp2 expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
CN104583401A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节atp2a2表达的组合物和方法
BR112014028631A2 (pt) 2012-05-16 2017-10-17 Rana Therapeutics Inc composições e métodos para modulação da expressão da família de genes da hemoglobina
EP2857513A4 (en) 2012-05-26 2016-05-25 Bonac Corp Single-stranded nucleic acid molecule controlling the expression of a gene transporter
EP2895200B1 (en) 2012-09-14 2019-11-06 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
CA2902432A1 (en) 2013-03-12 2014-10-09 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
US9981047B2 (en) 2013-08-19 2018-05-29 Thomas Lars Andresen Peptidic nanodelivery composition targeting two receptors
CA2915728A1 (en) 2013-08-21 2015-02-26 Thomas Kramps Respiratory syncytial virus (rsv) vaccine
US10174328B2 (en) 2013-10-04 2019-01-08 Translate Bio Ma, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2015099122A1 (ja) 2013-12-26 2015-07-02 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
RU2697094C2 (ru) 2013-12-27 2019-08-12 Бонак Корпорейшн ИСКУССТВЕННАЯ мкРНК С СООТВЕТСТВИЕМ ДЛЯ КОНТРОЛЯ ЭКСПРЕССИИ ГЕНОВ И ЕЕ ПРИМЕНЕНИЕ
ES2877356T3 (es) 2014-01-27 2021-11-16 Molecular Templates Inc Epítopo de MHC de clase I que suministra polipéptidos
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
JP6935195B2 (ja) * 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
US10273484B2 (en) 2014-03-24 2019-04-30 Riboxx Gmbh Double-stranded RNA conjugates and their use
DK3139965T3 (da) 2014-05-07 2021-11-22 Applied Molecular Transport Inc Fusionsmolekyler afledt af cholix-toksin til oral indgivelse af biologisk aktive stoffer
AU2015274647C1 (en) 2014-06-11 2020-01-30 Molecular Templates, Inc. Protease-cleavage resistant, Shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
EP3200819A4 (en) * 2014-09-30 2018-05-16 The Medical College of Wisconsin, Inc. Universal platform for targeting therapies to treat neurological diseases
US20170333571A1 (en) * 2014-11-04 2017-11-23 The Regents Of The University Of California Targeted Delivery Platform for Delivery of Therapeutics
CA2971827A1 (en) 2014-12-27 2016-06-30 Bonac Corporation Naturally occuring mirna for controlling gene expression, and use of same
MX2017010072A (es) 2015-02-05 2017-11-09 Molecular Templates Inc Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
CN108064289A (zh) 2015-03-27 2018-05-22 株式会社博纳克 具有递送功能和基因表达调控能力的单链核酸分子
MX2017015493A (es) 2015-05-30 2018-02-09 Molecular Templates Inc Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
AU2016335158A1 (en) * 2015-10-05 2018-04-12 Devgen Nv Methods of preserving the biological activity of ribonucleic acids
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
JP7082424B2 (ja) 2017-01-25 2022-06-08 モレキュラー テンプレーツ，インク． 脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子
IL319835A (en) 2017-12-06 2025-05-01 Avidity Biosciences Inc Compositions and methods for treating muscular dystrophy and myotonic dystrophy
SG11202009925PA (en) 2018-03-08 2020-11-27 Applied Molecular Transport Inc Toxin-derived delivery constructs for oral delivery
EP3768708A4 (en) * 2018-03-23 2022-08-03 The Regents of the University of California METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY
WO2019204272A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
EP3818167A4 (en) * 2018-07-05 2022-04-13 The Regents of The University of California COMPOSITIONS AND METHODS FOR DELIVERING RNA TO A CELL
CA3119179A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Cholix-derived carriers for oral delivery of heterologous payload
AU2019377117B2 (en) 2018-11-07 2025-05-29 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
JP2022544624A (ja) 2019-08-16 2022-10-19 アプライド モレキュラー トランスポート インコーポレイテッド 組成物、製剤およびインターロイキンの生成および精製
EP3868882A1 (en) * 2020-02-21 2021-08-25 European Molecular Biology Laboratory Archaeal pyrrolysyl trna synthetases for orthogonal use
US11555190B2 (en) 2020-03-19 2023-01-17 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
US20230158061A1 (en) * 2020-04-23 2023-05-25 Cornell University Nanotherapy Targeting RHAMM-Positive Tumors
KR20240055874A (ko) 2021-09-16 2024-04-29 어비디티 바이오사이언시스 인크. 안면견갑상완 근이영양증을 치료하는 조성물 및 방법
US20240398936A1 (en) * 2021-10-26 2024-12-05 Navicure Biopharmaceuticals Limited Immunogenic fusion proteins against coronavirus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
ATE247488T1 (de) * 1995-10-13 2003-09-15 Us Gov Health & Human Serv Immunotoxin enthaltend ein disulfid- stabilisiertes antikörperfragment
JP2001504334A (ja) * 1996-11-06 2001-04-03 アメリカ合衆国 プロテアーゼ活性化可能なＰｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様プロタンパク質
US6740643B2 (en) 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
US8211468B2 (en) 1999-06-07 2012-07-03 Arrowhead Madison Inc. Endosomolytic polymers
AU2002236499A1 (en) 2000-11-30 2002-06-11 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
DK1379550T3 (da) * 2000-12-21 2009-07-06 Us Gov Health & Human Serv Et kimært protein omfattende non-toxisk pseudomonas exotoxin A og en type IV pilin sekvenser
US20030133912A1 (en) 2001-12-11 2003-07-17 Davidson Beverly L. Receptor-targeted adenoviral vectors
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
AU2004316996A1 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
US20100240597A1 (en) * 2007-06-15 2010-09-23 Arkansas State University Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
EP2205740A2 (en) 2007-10-02 2010-07-14 Rxi Pharmaceuticals Corp. Tripartite rnai constructs

Also Published As

Publication number Publication date
EP2456470A1 (en) 2012-05-30
WO2011009624A1 (en) 2011-01-27
US20120258104A1 (en) 2012-10-11
JP2012533587A (ja) 2012-12-27

Similar Documents

Publication Publication Date Title
US20120258104A1 (en) Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes
US20140065172A1 (en) Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
US20240309058A1 (en) Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
Gooding et al. siRNA delivery: from lipids to cell‐penetrating peptides and their mimics
CN108368507B (zh) 程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
AU2016251415B9 (en) C/EBP alpha saRNA compositions and methods of use
US20230031703A1 (en) Stabilized hnf4a sarna compositions and methods of use
JP2011505846A (ja) ポリペプチド−核酸コンジュゲートおよびその使用
US20060040882A1 (en) Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
TW202535432A (zh) 抑制lpa表現之組合物及方法
KR20220156880A (ko) Angptl3 발현을 저해하기 위한 조성물 및 방법
US20130053426A1 (en) Composition For Delivery Of Genetic Material
WO2005117991A2 (en) Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
EA024534B1 (ru) КОНЪЮГИРОВАННАЯ СИСТЕМА ДОСТАВКИ И КОМПОЗИЦИЯ ДЛЯ НАПРАВЛЕННОЙ ДОСТАВКИ МАЛЫХ ИНТЕРФЕРИРУЮЩИХ РНК (миРНК) И СПОСОБ ПОЛУЧЕНИЯ КОМПОЗИЦИИ
US20200208152A1 (en) Stabilized sarna compositions and methods of use
Su et al. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth
US20200370052A1 (en) Pattern recognition receptor agonist prodrugs and methods of use thereof
EP1934359A2 (en) Pharmaceutical compositions for delivery of ribonucleic acid to a cell
ES2526109B1 (es) Péptido y composición farmacéutica para el tratamiento del cáncer
WO2011135140A1 (es) Método para la administración de oligonucleótidos
KR20220117091A (ko) 생체내 세포에서 합성 및 분비되고 세포로 투과하는 관심 폴리펩타이드를 코딩하는 발현카세트 및 이의 용도
US12006502B2 (en) Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
KR20250005108A (ko) Scap 활성을 조절하기 위한 조성물 및 방법
Arnold Bioconjugate Strategies for Antisense Therapeutic Delivery to Glioblastoma Stem Cells
HK1152548A (en) Polypeptide-nucleic acid conjugates and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130821

FZDE Discontinued

Effective date: 20160420